EU Backs Down In Row Over AstraZeneca Vaccine Supplies
Company Offers 9 Million Extra Doses
The European Commission has averted all-out conflict with AstraZeneca and the UK government, with good news from J&J and Pfizer/BioNTech easing supply concerns.
You may also be interested in...
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
The European Commission wants to learn from mistakes made in the COVID-19 crisis and to create an end-to-end system to co-ordinate funding, clinical research and manufacturing of vaccines.
Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.